مقایسه سطح تستوسترون، دهیدرواپی آندرسترون سولفات و شاخص‌های تن‌سنجی بین بیماران مبتلا به سندرم تخمدان پلی‌کیستیک مصرف کننده متفورمین و سیپروترون کامپاند

نوع مقاله : اصیل پژوهشی

نویسندگان

1 دانشجوی پزشکی، دانشکده پزشکی، دانشگاه علوم پزشکی آبادان، آبادان، ایران.

2 استادیار گروه علوم تغذیه، دانشکده پزشکی، دانشگاه علوم پزشکی آبادان، آبادان، ایران.

3 استادیار گروه علوم تشریحی، دانشکده پزشکی، دانشگاه علوم پزشکی آبادان، آبادان، ایران.

4 استادیار گروه آمار حیاتی، دانشکده بهداشت، دانشگاه علوم پزشکی آبادان، آبادان، ایران.

5 استادیار گروه زنان و مامایی، دانشکده پزشکی، دانشگاه علوم پزشکی آبادان، آبادان، ایران.

چکیده

مقدمه: سندرم تخمدان پلی‌کیستیک (PCOS) با هیپرآندروژنیسم و چاقی ارتباط دارد. مطالعۀ حاضر با هدف مقایسۀ سطح تستوسترون، دهیدرواپی آندرسترون سولفات و شاخص­ های تن­ سنجی بین بیماران مبتلا به PCOS مصرف کننده متفورمین و سیپروترون کامپاند انجام شد.
روش‌کار: این مطالعه مقطعی- تحلیلی در سال 1401 با مرور مستندات پزشکی شامل سن، شاخص تودۀ بدنی (BMI)، محیط دور کمر (WC)، نسبت دور کمر به دور باسن (WHR)، نسبت دور کمر به قد (WHtR)، سطح سرمی تستوسترون و دی هیدروکسی اپی آندرسترون سولفات قبل و بعد از مصرف دارو به‌مدت 3 ماه انجام شد. 220 شرکت کننده در 4 گروه 55 نفره: 1) مصرف کنندۀ متفورمین 500 میلی‌گرم روزانه، 2) مصرف کنندۀ سیپروترون کامپاند 2 میلی‌گرم روزانه، 3) مصرف کنندۀ همزمان متفورمین و سیپروترون کامپاند به‌طور همزمان و 4) شرکت کنندگان فاقد PCOS به‌عنوان کنترل قرار گرفتند. تجزیه و تحلیل­ داده‌ها با استفاده از نرم‌افزار آماری SPSS (نسخه 25) و آزمون‌های تی زوجی و آنووا انجام شد. میزان p کمتر از 05/0 معنی­ دار در نظر گرفته شد.
یافته ­ها: قبل از مداخله، میانگین سطوح سرمی تستوسترون و دی هیدروکسی اپی‌آندروسترون سولفات در گروه‌های مداخله به‌طور معنی‌داری بالاتر از گروه کنترل فاقد PCOS بود (به‌ترتیب 001/0>p و 005/0=p) که پس از مداخله این اختلاف معنی‌دار نبود (به‌ترتیب 111/0=p و 423/0=p). علاوه بر این، مصرف متفورمین به­ تنهایی باعث افزایش BMI (001/0=p) و WC (001/0=p) و کاهش WHtR (026/0=p) نسبت به گروه کنترل شد. مصرف همزمان داروهای متفورمین و سیپروترون کامپاند با کاهش میانگین WC در مقایسه با گروه کنترل همراه بود (001/0=p).
نتیجه ­گیری: مصرف متفورمین و سیپروترون کامپاند به­ تنهایی یا به­ طور همزمان، اثری بر سطح سرمی آندروژن ها ندارد. تجویز همزمان متفورمین و سیپروترون کامپاند در PCOS ممکن است چاقی شکمی را در بیماران PCOS کاهش دهد.

کلیدواژه‌ها

عنوان مقاله [English]

Testosterone and dehydroepiandrosterone sulfate serum levels and anthropometric indices among patients with polycystic ovary syndrome taking metformin and cyproterone compound

نویسندگان [English]

  • Mina Mohseni Shooshtari 1
  • Mahshid Naqhashpour 2
  • Firozeh Niazvand 3
  • Naser Kamyari 4
  • Nazila Zandi 5
1 Medical Student, Faculty of Medicine, Abadan University of Medical Sciences, Abadan, Iran.
2 Assistant professor, Department of Nutrition Sciences, Faculty of Medicine, Abadan University of Medical Sciences, Abadan, Iran.
3 Assistant professor, Department of Anatomical Sciences, Faculty of Medicine, Abadan University of Medical Sciences, Abadan, Iran.
4 Assistant professor, Department of Vital Statistics, School of Health, Abadan University of Medical Sciences, Abadan, Iran.
5 Assistant professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Abadan University of Medical Sciences, Abadan, Iran.
چکیده [English]

Introduction: Polycystic Ovary Syndrome (PCOS) is associated with hyperandrogenism and obesity. The present study was performed with aim to compare testosterone and dehydroepiandrosterone sulfate serum levels and anthropometric indices between patients with PCOS taking metformin and cyproterone compounds.
Methods: This cross-sectional analytical study was conducted in 2022 was performed by reviewing the medical documents including age, body mass index (BMI), waist circumference (WC), waist-to-hip-ratio (WHR), waist-to-height ratio (WHtR), testosterone serum levels, and dehydroepiandrosterone sulfate before and after taking the drugs for 3 months. Two-hundred and twenty participants were divided in 4 groups (n=55 in each group) as follows: 1) taking metformin 500 mg daily, 2) taking cyproterone compound 2 mg daily, 3) taking metformin and cyproterone compound simultaneously, and 4) participants without PCOS as control. Data were analyzed by SPSS software (version 25) and paired T-test and ANOVA. P<0.05 was consider statistically significant.
Results: Before the intervention, the mean serum levels of testosterone and dihydroxyepiandrosterone sulfate were significantly higher in the intervention groups compared to the control group without PCOS (p<0.001 and p=0.005, respectively). This difference was not significant after the intervention (p=0.111 and p=0.423, respectively). However, taking metformin alone increased BMI (p= 0.001) and WC (p= 0.001) and decreased WHtR (p= 0.026) compared to the control group. Taking metformin and cyproterone compounds simultaneously were associated with a decrease in WC compared to the control group (p= 0.001).
Conclusion: Taking metformin and cyproterone compounds alone or simultaneously has no effect on the androgens serum level. Co-administration of metformin and cyproterone compounds may reduce abdominal obesity in PCOS patients.

کلیدواژه‌ها [English]

  • Keywords: BMI
  • Cyproterone acetate
  • Metformin
  • Polycystic ovary syndrome
  • Testosterone

مراجع

  1. Ehrmann DA. Polycystic ovary syndrome. New England Journal of Medicine 2005; 352(12):1223-36.
  2. Urbanek M. The genetics of the polycystic ovary syndrome. Nature clinical practice Endocrinology & metabolism 2007; 3(2):103-11.
  3. Elizabeth M, Leslie NS, Critch EA. Managing polycystic ovary syndrome: a cognitive behavioral strategy. Nursing for women's health 2009; 13(4):292-300.
  4. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clinical endocrinology 2004; 60(1):1-7.
  5. Barber TM, Franks S. Genetics of polycystic ovary syndrome. Polycystic ovary syndrome 2013; 40:28-39.
  6. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertility and sterility 2003; 80(1):123-7.
  7. Tarlatzis BC, Fauser BC, Legro RS, Norman RJ, Hoeger K, Pasquali R, et al. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction 2008; 23(3):462-77.
  8. Homburg R. Polycystic ovary syndrome. Best Practice & Research Clinical Obstetrics & Gynaecology 2008; 22(2):261-74.
  9. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long‐term follow‐up: a retrospective cohort study. Clinical endocrinology 2000; 52(5):595-600.
  10. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertility and sterility 2002; 77(3):520-5.
  11. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor–social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Human Reproduction 2004; 19(6):1323-30.
  12. Amiri M, Golsorkhtabaramiri M, Esmaeilzadeh S, Ghofrani F, Bijani A, Ghorbani L, et al. Effect of metformin and flutamide on anthropometric indices and laboratory tests in obese/overweight PCOS women under hypocaloric diet. Journal of reproduction & infertility 2014; 15(4):205.
  13. Abdalla MA, Shah N, Deshmukh H, Sahebkar A, Östlundh L, Al‐Rifai RH, et al. Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta‐analysis of randomized controlled trials. Clinical Endocrinology 2022; 96(3):371-94.
  14. Machin D. Comparing two independent groups for binary, ordered categorical and continuous data. Sample size tables for clinical studies 1997: 18-68.
  15. Björntorp P. The android woman–a risky condition. Journal of Internal Medicine 1996; 239(2):105-10.
  16. Baillargeon JP, Carpentier A. Respective role of insulin and LH in the ovarian steroidogenic production of non-obese women with PCOS and normal insulin levels-preliminary results. Annual Scientific Meeting of the Endocrine Society.
  17. Edition S, Ryan KJ, Berkowitz RS, Barbieri RL, Dunaif A. Kistner's Gynecology and Women's Health (Doctoral dissertation, Brigham and Women's Hospital Boston, Massachusetts); 1999.
  18. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology & Metabolism 2000; 85(9):3161-8.
  19. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. The lancet 2003; 361(9371):1810-2.
  20. Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. The Lancet 2003; 361(9372):1894-901.
  21. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. The Journal of Clinical Endocrinology & Metabolism 2000; 85(1):139-46.
  22. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertility and sterility 2000; 73(6):1149-54.
  23. Baillargeon JP. Use of insulin sensitizers in polycystic ovarian syndrome. Current Opinion in Investigational Drugs (London, England: 2000) 2005; 6(10):1012-22.
  24. Homburg R. Should patients with polycystic ovarian syndrome be treated with metformin? A note of cautious optimism. Human Reproduction 2002; 17(4):853-6.
  25. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999; 48(4):511-9.
  26. El Biely MM, Habba M. The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome; 2001.
  27. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. The Journal of Clinical Endocrinology & Metabolism 2002; 87(2):569-74.
  28. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. The Journal of Clinical Endocrinology & Metabolism 1998; 83(7):2317-23.
  29. Ersoy AO, Tokmak A, Ozler S, Oztas E, Ersoy E, Celik HT, et al. Are progranulin levels associated with polycystic ovary syndrome and its possible metabolic effects in adolescents and young women?. Archives of gynecology and obstetrics 2016; 294:403-9.
  30. Christodoulaki C, Trakakis E, Pergialiotis V, Panagopoulos P, Chrelias C, Kassanos D, et al. Dehydroepiandrosterone-sulfate, insulin resistance and ovarian volume estimation in patients with polycystic ovarian syndrome. Journal of Family & Reproductive Health 2017; 11(1):24.
  31. Ghandi S, Aflatoonian A, Tabibnejad N, Moghaddam MH. The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. Journal of assisted reproduction and genetics 2011; 28:591-6.
  32. Chow SC, Wang H, Shao J. Sample size calculations in clinical research. 2nd New York: CRC press; 2007.
  33. Amiri M, Golsorkhtabaramiri M, Esmaeilzadeh S, Ghofrani F, Bijani A, Ghorbani L, et al. Effect of metformin and flutamide on anthropometric indices and laboratory tests in obese/overweight PCOS women under hypocaloric diet. Journal of reproduction & infertility 2014; 15(4):205-13.
  34. Agrawal A, Mahey R, Kachhawa G, Khadgawat R, Vanamail P, Kriplani A. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecological Endocrinology 2019; 35(6):511-4.
  35. Ruan X, Kubba A, Aguilar A, Mueck AO. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. The European Journal of Contraception & Reproductive Health Care 2017; 22(3):183-90.
  36. Hunter GR, Snyder SW, Kekes‐Szabo T, Nicholson C, Berland L. Intra‐abdominal adipose tissue values associated with risk of possessing elevated blood lipids and blood pressure. Obesity research 1994; 2(6):563-8.
  37. Orbetsova M, Kamenov Z, Kolarov G, Zakharieva S, Khristov V, Atanasova I, et al. Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy. Akusherstvo i Ginekologiia 2006; 45(7):16-28.
  38. Ferreira Santana L, Silva de Sa MF, Ferriani RA, De Moura MD, Foss MC, Dos Reis RM. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecological endocrinology 2004; 19(2):88-96.
  39. Liqun L, Yi L, Yongyu S, Kan T. Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology [Medical Sciences] 2005; 25:194-7.
  40. Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol–cyproterone acetate in polycystic ovary syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology 2005; 118(2):209-13.
  41. Jing Z, Liang-Zhi X, Tai-Xiang W, Ying T, Yu-Jian J. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. Gynecological Endocrinology 2008; 24(10):590-600.
  42. Feng W, Jia YY, Zhang DY, Shi HR. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology 2016; 32(2):147-50.
  43. Badri-Fariman M, Naeini AA, Mirzaei K, Moeini A, Hosseini M, Bagheri SE, et al. Association between the food security status and dietary patterns with polycystic ovary syndrome (PCOS) in overweight and obese Iranian women: a case-control study. Journal of Ovarian Research 2021; 14:1-14.
  44. Neves LP, Marcondes RR, Maffazioli GD, Simões RS, Maciel GA, Soares Jr JM, et al. Nutritional and dietary aspects in polycystic ovary syndrome: insights into the biology of nutritional interventions. Gynecological Endocrinology 2020; 36(12):1047-50.
  45. Kite C, Lahart IM, Afzal I, Broom DR, Randeva H, Kyrou I, et al. Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Systematic reviews 2019; 8:1-28.
  46. Abedini M, Ghaedi E, Hadi A, Mohammadi H, Amani R. Zinc status and polycystic ovarian syndrome: A systematic review and meta-analysis. Journal of Trace Elements in Medicine and Biology 2019; 52:216-21.
  47. Foroozanfard F, Rafiei H, Samimi M, Gilasi HR, Gorjizadeh R, Heidar Z, et al. The effects of dietary approaches to stop hypertension diet on weight loss, anti‐Müllerian hormone and metabolic profiles in women with polycystic ovary syndrome: a randomized clinical trial. Clinical endocrinology 2017; 87(1):51-8.
  48. Eslamian G, Hekmatdoost A. Nutrient patterns and risk of polycystic ovary syndrome. Journal of Reproduction & Infertility 2019; 20(3):161.
  49. Panjeshahin A, Salehi-Abargouei A, Anari AG, Mohammadi M, Hosseinzadeh M. Association between empirically derived dietary patterns and polycystic ovary syndrome: a case-control study. Nutrition 2020; 79:110987.
  50. Jafari-Sfidvajani S, Ahangari R, Hozoori M, Mozaffari-Khosravi H, Fallahzadeh H, Nadjarzadeh A. The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Journal of Endocrinological Investigation 2018; 41:597-607.
  51. Ganie MA, Sahar T, Rashid A, Wani IA, Nisar S, Sathyapalan T, et al. Comparative evaluation of biomarkers of inflammation among Indian women with polycystic ovary syndrome (PCOS) consuming vegetarian vs. non-vegetarian diet. Frontiers in endocrinology 2019; 10:699.
  52. Muscogiuri G, Palomba S, Laganà AS, Orio F. Current insights into inositol isoforms, Mediterranean and ketogenic diets for polycystic ovary syndrome: from bench to bedside. Current Pharmaceutical Design 2016; 22(36):5554-7.
  53. Morgante G, Massaro MG, Di Sabatino A, Cappelli V, De Leo V. Therapeutic approach for metabolic disorders and infertility in women with PCOS. Gynecological Endocrinology 2018; 34(1):4-9.
  54. Mhao NS, Al-Hilli AS, Hadi NR, Jamil DA, Al-Aubaidy HA. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2016; 10(1):S95-8.
  55. Omran MY. Metformin and polycystic ovary syndrome. International journal of health sciences 2007; 1(1):75.
مجله زنان، مامایی و نازایی ایران
دوره 26، شماره 4
تیر 1402
صفحه 59-73

فایل ها

هم رسانی

ارجاع به این مقاله

آمار